Disulfiram, an alcohol-aversion drug, inhibits GSDMD pore formation and shows protective effects in sepsis models, though its relatively narrow therapeutic window and neurological side effects at higher doses may limit clinical utility in COPD populations (96). Here, GSDMD is linked to chronic obstructive pulmonary disease.